

Clinical Trials Advancement and Methods PIA Business Meeting Summary

Location: ExCel London (Platinum Suite 1)

Date: Saturday, July 15, 2017

Time: 9 - 10 a.m.

**PIA Chair(s)/Meeting
Facilitator(s):** Hiroko Dodge

- **10 Attendees**
- **Upcoming elections:**
 - The PIA would like the Chair (and Co-Chair(s), if needed) to hold a 3 year term; the 3rd year will be the transition period
 - Modified bylaws will be circulated among members at the time of Fall election (when soliciting nominations). Yumeka provided a Microsoft Word template of Bylaws earlier.
- **Progress:**
 - We provided the first Clinical Trials Methods Workshop this year as pre-conference workshop: 61 registrants for the Workshop
 - Membership grew over 600 (second largest following Imaging Core)
 - 3rd year to provide the PIA scientific symposium at PIA day, AAIC (PIA day symposium successfully completed (see below for the full schedule*))
- **2017-2018 Goals:**
 - Fall Elections
 - Organize another method pre-conference workshop (2018 AAIC at Chicago)
 - Revitalize working group activities (the elected new chair will contact working group leaders to facilitate symposium abstracts submission to AAIC—early Spring, after the election).
 - Establish new working groups at 2018 AAIC
 - Increase membership
- **Action Items:**
 - Yumeka will distribute a Call for Nominations email to the PIA membership
 - PIA Chairs will create a shortlist of nominations
 - Provide the Executive Committee the workshop results in August

*PIA day schedule:

NEW PERSPECTIVES IN AD CLINICAL TRIAL APPROACHES

- Opening remarks, Hiroko Dodge (Oregon Health & Science University and University of Michigan) 7:32- 7:35
- Howard Feldman (University of California San Diego): Re-approaching proof of concept: emerging opportunities 7:35 – 7:52

- Michael Lutz (Duke University): Application of molecular understanding of AD to clinical development: lessons from cancer research 7:52 – 8:09
- Todd Golde (University of Florida): Disruptive approaches to development and testing of new AD therapies 8:09 – 8:26
- Lon S Schneider (Keck School of Medicine of USC): Phase 3 trials have failed because their phase 2 trials were uninformative: The need to learn some stuff 8:26 – 8:43

UPDATES ON INTERNATIONAL CONSORTIUM AND INTRODUCTION OF NEW INITIATIVES

- Craig Ritchie (University of Edinburgh): What's new and exciting from the European Prevention of Alzheimer's Dementia Consortium (EPAD) 8:45 – 8:55
- Kaarin Anstey (the Australian National University): Introduction of IRNDP Initiative 8:55-9:00

Minutes taken by: April Ross and Ari Buhaumick